Touti, F., Lautrette, G., Johnson, K.D., Delaney, J.C., Wollacott, A., Tissire, H., et al., ChemBioChem , 2018, vol
However, instead of enhancing tumor antigen transportation and immune cell trafficking to the TDLNs, tumor-associated lymphatic endothelium can impede anti-cancer T-cell response and promote cancer cell immune evasion and metastasis (9397) ( Figure 1 )
Metabolism & Elimination The metabolic fate of KLOW Blend involves parallel processing of four distinct peptides [20]: BPC-157: Plasma half-life under 30 minutes but biological effects persist for hours to days TB-500: Estimated 2-3 hour half-life with C-terminal degradation patterns GHK-Cu: Estimated 2-4 hour half-life involving copper release and peptide fragmentation KPV: Estimated 1-2 hour half-life with rapid peptidase degradation to amino acids Complex interactions between components may influence individual clearance rates All components metabolize to amino acids that enter normal metabolic pathways A significant pharmacokinetic paradox exists across all components: despite rapid plasma clearance (30 minutes to 4 hours), biological effects often persist well beyond plasma elimination, suggesting tissue retention, active metabolite formation, persistent signaling cascade activation, or gene expression changes that outlast peptide presence
A 2025 pilot human IV study at 1020mg reported a favorable safety profile with no serious adverse events
